ArticlePloS one2022
Economic burden of sickle cell disease in Brazil.
Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Analgesic Utilization Pattern and Cost of Managing Children with Sickle Cell Diseases: a Retrospective Single-site Audit.Journal of racial and ethnic health disparities · 2026Article
- Risk of vaso-occlusive crisis requiring hospitalization in sickle cell disease patients in brazil: retrospective cohort study of real-world data.Annals of hematology · 2026Article
- Laboratory and genetic characteristic associated with gallbladder-related outcomes in sickle cell disease in Brazil: results from the REDS-III multicenter cohort study.Annals of hematology · 2026Article
- Article
- Neurocognitive functioning of patients with sickle cell disease in low- and middle-income countries.Blood global hematology · 2025Article
- Hydroxyurea Therapy in Sickle Cell Disease: Evaluating Healthcare Costs and Utilization in a Brazilian Tertiary Setting.Blood global hematology · 2025Article
- Economic burden of sickle cell disease in Australia.Internal medicine journal · 2025Article
- WHOQOL-BREF in Measuring Quality of Life Among Sickle Cell Disease Patients with Leg Ulcers.International journal of environmental research and public health · 2025Article
- Epidemiological profile trends and cost of sickle cell disease in Brazil from 2008 to 2022.Acta cirurgica brasileira · 2025Article
- Article
- Comparing super-utilizers and lower-utilizers among commercial- and Medicare-insured adults with sickle cell disease.Blood advances · 2024Article
- Real-world evidence of the burden of sickle cell disease: a 5-year longitudinal study at a Brazilian reference center.Hematology, transfusion and cell therapyArticle
- Updating the Brazilian clinical practice guidelines for sickle cell disease: Recommendations and development process.Hematology, transfusion and cell therapyArticle
- Epidemiological profile trends and cost of pediatric sickle cell disease in Brazil from 2008 to 2022.Jornal de pediatriaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSickle cell disease (SCD) may cause several impacts to patients and the whole society. About 4% of the population has the sickle cell trait in Brazil, and 60,000 to 100,000 have SCD. However, despite recognizing the significant burden of disease, little is known about SCD costs.
objectiveTo estimate SCD societal costs based on disease burden modelling, under Brazilian societal perspective.
methodsA disease burden model was built considering the societal perspective and a one-year time horizon, including direct medical and indirect costs (morbidity and mortality). The sum of life lost and disability years was considered to estimate disability-adjusted life years (DALYs). Data from a public database (DATASUS) and the prevalence obtained from literature or medical experts were used to define complications prevalence and duration. Costs were defined using data from the Brazilian public healthcare system table of procedures and medications (SIGTAP) and the human capital method.
resultsAnnual SCD cost was 413,639,180 USD. Indirect cost accounted for the majority of burden (70.1% of the total; 290,158,365 USD vs 123,480,816 USD). Standard of care and chronic complications were the main source of direct costs among adults, while acute conditions were the main source among children. Vaso-occlusive crisis represented the complication with the highest total cost per year in both populations, 11,400,410 USD among adults and 11,510,960 USD among children.
conclusionsSCD management may impose an important economic burden on Brazilian society that may reach more than 400 million USD per year.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.